2 active not recruiting, 2 completed, 1 terminated, 1 withdrawn. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Ovarian Serous Tumor: new trials by email Literature Review of Ovarian Serous Tumor trials Research Report on Ovarian Serous Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Auranofin and Sirolimus in Treating Participants With Ovarian Cancer Auranofin, Laboratory Biomarker Analysis, Sirolimus - Ovarian Serous Tumor, Recurrent Ovarian Carcinoma | Phase 2 | Terminated | Mayo Clinic | 22 | 2018-03-30 | 2025-05-08 |
| Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Laboratory Biomarker Analysis, Monitoring Device, Physical Activity - Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm | Phase 2 | Completed | Roswell Park Cancer Institute | 9 | 2017-06-27 | 2021-09-02 |
| Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Berzosertib, Gemcitabine, Gemcitabine Hydrochloride - Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2016-08-25 | 2026-09-09 |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Biospecimen Collection, Carboplatin, Cediranib Maleate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 579 | 2016-03-28 | 2026-10-01 |
| Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Hsp90 Inhibitor AT13387, Laboratory Biomarker Analysis, Pharmacological Study - Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2016-03-01 | 2016-07-26 | |
| Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer Dexamethasone, Laboratory Biomarker Analysis, Valproic Acid - Adnexal Mass, Borderline Ovarian Epithelial Tumor | Phase 1 | Completed | Barbara Ann Karmanos Cancer Institute | 50 | 2015-08-01 | 2019-08-14 |
Ovarian Neoplasms (6) · Fallopian Tube Neoplasms (4) · Breast Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Adnexal Diseases (6) · Endocrine Gland Neoplasms (6) · Endocrine System Diseases (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Gonadal Disorders (6) · Neoplasms (6) · Neoplasms by Site (6) · Ovarian Diseases (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Fallopian Tube Diseases (4)
Gemcitabine (2) · (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1) · Auranofin (1) · Calcium Dobesilate (1) · Carboplatin (1) · Dexamethasone (1) · Doxorubicin (1) · Exercise (1) · Magnetic Resonance Spectroscopy (1) · Monitoring, Physiologic (1) · Paclitaxel (1) · Sirolimus (1) · Specimen Handling (1) · Taxes (1) · Valproic Acid (1)
National Cancer Institute (NCI) (3) · Barbara Ann Karmanos Cancer Institute (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1)
United States (5) · Canada (1) · Japan (1) · South Korea (1)
Aminah Jatoi, M.D. (1) · Emese Zsiros (1) · Ira Winer (1) · Joyce F Liu (1) · Panagiotis A Konstantinopoulos (1) · Panagiotis Konstantinopoulos (1)
PMID 32553118, PMID 35170751, PMID 35254001, PMID 35290101, PMID 37185961, PMID 38635934, PMID 41114938
UM1CA186709 (2), P30CA006516 (1), P30CA022453 (1), U10CA180868 (1)